India, April 15 -- MSN Laboratories has announced the launch of SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO).

This milestone reinforces the company's commitment to expanding access to advanced therapies for chronic metabolic diseases, including type 2 diabetes. SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration.

Since 20th March 2026, the market has seen a surge of new entrants. In this evolving landscape, SEMABEST stands apart with its strong backward integration across in-house USDM...